WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
China launches new remote sensing satellite3 scientists share 2023 Nobel Prize in PhysicsBBC presenter confirms departure from 'lifeDetectives solve 1968 killing of World War II veteran who became milkman, Florida sheriff saysDetectives solve 1968 killing of World War II veteran who became milkman, Florida sheriff saysChina's ShenzhouChinese researchers call for increase in advanced carbon observation stationsXi, Lula congratulate seminar on exchangesWorld Internet SciChina's Shenzhou
2.5879s , 6497.3984375 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,Global Gleam news portal